CAM
VERV

Cormorant Asset Management’s Verve Therapeutics VERV Stock Holding History

Cormorant Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-350,000
Closed -$1.97M – 49
2024
Q4 		$1.97M Hold
350,000
– – 0.11% 46
2024
Q3 		$1.69M Hold
350,000
– – 0.09% 43
2024
Q2 		$1.71M Hold
350,000
– – 0.1% 48
2024
Q1 		$4.65M Hold
350,000
– – 0.2% 54
2023
Q4 		$4.88M Hold
350,000
– – 0.23% 41
2023
Q3 		$4.64M Hold
350,000
– – 0.27% 39
2023
Q2 		$6.56M Hold
350,000
– – 0.37% 46
2023
Q1 		$5.05M Hold
350,000
– – 0.33% 47
2022
Q4 		$6.77M Sell
350,000
-250,000
-42% -$6.62M 0.45% 47
2022
Q3 		$20.6M Sell
600,000
-100,710
-14% -$3.21M 1.44% 26
2022
Q2 		$10.7M Hold
700,710
– – 0.81% 39
2022
Q1 		$16M Sell
700,710
-408,514
-37% -$11.7M 1.23% 22
2021
Q4 		$40.9M Buy
1,109,224
+400,000
+56% +$16.8M 2.43% 11
2021
Q3 		$32.7M Hold
709,224
– – 1.33% 22
2021
Q2 		$40.6M Buy
+709,224
New +$29.4M 1.38% 25

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cormorant Asset Management's VERV Position: Q1 2025 in Review

Cormorant Asset Management sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 350,000 shares — an estimated $1.97M sold.

Cormorant Asset Management first reported a position in VERV in Q2 2021 and held it in 15 quarters. The position peaked at $40.9M in Q4 2021. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Cormorant Asset Management reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 350,000 Verve Therapeutics shares in Q1 2025, an estimated $1.97M.
  • Cormorant Asset Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 15 quarters.
  • Cormorant Asset Management's Verve Therapeutics position peaked at $40.9M in Q4 2021.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.